Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by RobertoLon Apr 14, 2023 3:55pm
141 Views
Post# 35395925

RepliCel investor acquires 4.02 million units

RepliCel investor acquires 4.02 million units

2023-04-14 14:52 ET - News Release

 

Mr. Jamie Mackay, an investor, reports

JAMIE MACKAY INCREASES POSITION IN REPLICEL LIFE SCIENCES INC.

Mr. Jamie Mackay has issued this press release pursuant to Part 3.1 of National Instrument 62-103 -- The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, with respect to RepliCel Life Sciences Inc. Mr. Mackay is a 10 per cent shareholder of the company. On March 14, 2023, Mr. Mackay acquired 4,021,500 units from the company in a private placement at a price of 10 cents per unit for proceeds of $402,150. Each unit consists of one common share and one-half of one share purchase warrant. One whole warrant entitles the holder thereof to purchase one additional share of the company at a price of 20 cents per share until March 14, 2027. Prior to the transaction, Mr. Mackay owned the following securities: (i) 6,013,037 shares held directly; and (ii) 2,851,000 warrants held directly to purchase an additional 2,851,000 shares. Prior to the transaction, Mr. Mackay directly owned 8,864,037 shares, on a partially diluted basis (assuming exercise of all warrants), which represented 16.15 per cent of the issued and outstanding shares as of March 13, 2023, based on 54,870,560 shares issued and outstanding as of such date.

Following the transaction, Mr. Mackay owned the following securities: (i) 10,034,537 shares held directly; and (ii) 4,861,570 warrants held directly to purchase an additional 4,861,570 shares. After the issuance of the units pursuant to the transaction, Mr. Mackay directly and indirectly owned and controlled 14,896,107 shares, on a partially diluted basis (assuming exercise of all warrants), which represents 21.32 per cent of the issued and outstanding shares as of March 14, 2023, based on 65,001,560 shares issued and outstanding as of such date.

Mr. Mackay acquired the securities of the company for investment purposes. Depending on economic or market conditions, or matters relating to the company, Mr. Mackay may choose to either acquire additional securities or dispose of securities of the company.

A copy of Mr. Mackay's early warning report will appear on the company's profile on SEDAR and may also be obtained by contacting Mr. Mackay at 307-414-3131.

© 2023 Canjex Publishing Ltd. All rights reserved.

<< Previous
Bullboard Posts
Next >>